airexar spiromax
teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - airexar spiromax er indisert for bruk hos voksne i alderen 18 år og eldre. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. kronisk obstruktiv lungesykdom (kols)airexar spiromax er indikert for symptomatisk behandling av pasienter med kols, med en fev1.
aldurazyme
sanofi b.v. - laronidase - mukopolysakkaridose i - andre alimentary tract and metabolism products, - aldurazyme er indikert for langsiktig enzym erstatning terapi hos pasienter med en bekreftet diagnose av mucopolysaccharidosis jeg (mps jeg; alfa-l-iduronidase mangel på) til å behandle nonneurological manifestasjoner av sykdommen.
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
alvesco 80 mikrog/ dose
covis pharma europe b.v. - ciklesonid - inhalasjonsaerosol, oppløsning - 80 mikrog/ dose
alvesco 160 mikrog/ dose
covis pharma europe b.v. - ciklesonid - inhalasjonsaerosol, oppløsning - 160 mikrog/ dose
atrovent 20 mikrog/ dose
boehringer ingelheim international gmbh - ipratropiumbromidmonohydrat - inhalasjonsaerosol, oppløsning - 20 mikrog/ dose
falakef 1000 mg
i.c.f. srl industria chimica fine - cefaleksinmonohydrat - tablett, filmdrasjert - 1000 mg
falakef 500 mg
i.c.f. srl industria chimica fine - cefaleksinmonohydrat - tablett, filmdrasjert - 500 mg
flutide 50 mikrog/ dose
glaxosmithkline as - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 50 mikrog/ dose